

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Genscript Biotech Corporation**  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 1548)

**VOLUNTARY ANNOUNCEMENT**  
**LEGEND PRESENTS FIRST-IN-HUMAN LB2102 RESULTS IN SOLID TUMORS**  
**AND NEW CARVYKTI® DATA IN MULTIPLE MYELOMA AT ASCO 2026**

This is a voluntary announcement made by Genscript Biotech Corporation (the “Company”).

Legend Biotech Corporation (“**Legend**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “SEC”) on 1 June 2026 (New York time) (after trading hours on 1 June 2026 in Hong Kong) and issued a press release announcing first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC), and also announcing new analyses from the CARTITUDE program. For details, please refer to the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000117184326003825/0001171843-26-003825-index.htm> and the press release as published on the Legend’s website available at <https://investors.legendbiotech.com/press-releases>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**GenScript Biotech Corporation**  
**Robin Meng**  
*Chairman and Executive Director*

Hong Kong, 1 June 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*